Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Per Share data, unless otherwise specified
12 Months Ended
Jul. 31, 2014
Jul. 31, 2013
Jul. 31, 2012
Revenues:      
Clinical laboratory services $ 58,689 $ 55,889 $ 59,403
Product revenues 32,850 32,526 37,722
Royalty and license fee income 4,408 5,292 5,958
Total revenues 95,947 93,707 103,083
Operating expenses:      
Cost of clinical laboratory services 38,948 38,251 36,305
Cost of product revenues 15,320 16,584 19,668
Research and development 3,141 3,889 6,293
Selling, general, and administrative 41,801 43,654 47,928
Provision for uncollectible accounts receivable 3,063 4,496 5,104
Legal fee expense 6,954 5,813 3,724
Legal settlements, net (3,100)    
Impairment charges     24,540
Total operating expenses 106,127 112,687 143,562
Operating loss (10,180) (18,980) (40,479)
Other income (expense):      
Interest (208) (54) 21
Other 194 5 77
Foreign exchange gain (loss) 289 80 (540)
Loss before income taxes (9,905) (18,949) (40,921)
(Provision) benefit for income taxes (72) 712 1,652
Net loss $ (9,977) $ (18,237) $ (39,269)
Net loss per common share:      
Basic and diluted (in Dollars per share) $ (0.23) $ (0.46) $ (1.01)
Weighted average common shares outstanding:      
Basic and diluted (in Shares) 42,561 39,607 38,798